
   
   
      
         
            Drug-_NNP Company_NNP Merger-_NNP Maniacs_NNP Need_MD Sedation_NNP
            

            In_IN the_DT wake_NN of_IN American_NNP Home_NNP Products_NNPS '_POS friendly_JJ bid_NN for_IN Warner-_NNP Lambert_NNP and_CC
Pfizer_NNP 's_POS $_$ 80_CD billion_CD (_( or_CC $_$ 74_CD billion_CD ,_, depending_VBG on_IN who_WP 's_VBZ counting_VBG )_) hostile_JJ
counter-offer_JJ (_( click_NN here_RB to_TO
read_VB an_DT "_'' Explainer_NNP "_'' on_IN hostile_JJ takeovers_NNS )_) ,_, expectations_NNS are_VBP growing_VBG that_IN we_PRP 're_VBP
going_VBG to_TO see_VB a_DT wave_NN of_IN mergers_NNS in_IN the_DT pharmaceutical_JJ industry_NN ._. Novartis_NNP ,_, Glaxo_NNP ,_,
Monsanto_NNP ,_, Schering-_NNP Plough_NNP ,_, Merck_NNP :_: Everyone_NN is_VBZ either_CC on_IN the_DT block_NN or_CC shopping_NN ._.
Whether_IN all_PDT this_DT buying_NN and_CC selling_VBG makes_VBZ economic_JJ sense_NN seems_VBZ somehow_RB beside_IN
the_DT point_NN ._. After_IN all_DT ,_, they_PRP do_VBP n't_RB call_VB it_PRP merger-_NN mania_NN for_IN nothing_NN ._.

            The_DT most_RBS perplexing_JJ thing_NN about_IN the_DT goings-on_NNS in_IN the_DT pharmaceutical_JJ
industry_NN ,_, though_RB ,_, is_VBZ not_RB that_IN drug-company_JJ CEOs_NNS would_MD rather_RB run_VB $_$ 70_CD billion_CD
companies_NNS rather_RB than_IN $_$ 30_CD billion_CD companies_NNS ._. Nor_CC is_VBZ it_PRP that_IN Pfizer_NNP 's_POS
bid--which_JJ ,_, remember_VB ,_, it_PRP could_MD have_VB made_VBN long_RB before_IN American_NNP Home_NNP Products_NNPS
came_VBD a-courting--seems_JJ driven_VBN as_IN much_JJ by_IN the_DT "_'' if_IN you_PRP want_VBP Warner-_NNP Lambert_NNP ,_, then_RB
I_PRP want_VBP Warner-_NNP Lambert_NNP "_'' impulse_NN as_IN anything_NN else_RB ._. These_DT ,_, after_IN all_DT ,_, are_VBP the_DT
basic_JJ ingredients_NNS of_IN many_JJ ,_, if_IN not_RB most_JJS ,_, mergers_NNS which_WDT has_VBZ something_NN to_TO do_VB with_IN
the_DT fact_NN that_IN most_JJS mergers_NNS destroy_VBP ,_, and_CC do_VBP n't_RB create_VB ,_, economic_JJ value_NN ._.

            No_DT ,_, the_DT most_RBS perplexing_JJ thing_NN about_IN all_PDT the_DT merger_NN talk_NN is_VBZ the_DT reaction_NN of_IN
investors_NNS ,_, who_WP have_VBP driven_VBN up_RP the_DT prices_NNS of_IN pharmaceutical_JJ stocks_NNS pretty_RB much_JJ
across_IN the_DT board_NN ._. Since_IN acquisitions_NNS almost_RB universally_RB occur_VB at_IN a_DT price_NN above_IN
the_DT current_JJ market_NN price_NN ,_, and_CC since_IN bidding_NN wars_NNS (_( of_IN all_DT kinds_NNS )_) tend_VBP to_TO drive_VB
prices_NNS far_IN above_IN fair_JJ value_NN ,_, investors_NNS have_VBP jumped_VBN into_IN the_DT drug_NN stocks_NNS ,_,
assuming_VBG that_IN merger-mania_JJ has_VBZ to_TO be_VB good_JJ for_IN them_PRP ._.

            Here_RB 's_VBZ the_DT problem_NN ,_, though_IN :_: There_EX are_VBP no_DT outside_JJ bidders_NNS for_IN these_DT
companies_NNS ._. The_DT only_JJ company_NN that_WDT 's_VBZ going_VBG to_TO buy_VB a_DT Glaxo_NNP is_VBZ another_DT drug_NN
company_NN ._. So_RB ,_, there_EX is_VBZ n't_RB any_DT flood_NN of_IN outside_JJ capital_NN coming_VBG into_IN the_DT drug_NN
industry_NN ._. If_IN a_DT wave_NN of_IN mergers_NNS gets_VBZ touched_VBN off_RP ,_, all_DT that_DT 's_VBZ going_VBG to_TO happen_VB is_VBZ
that_DT capital_NN will_MD be_VB redistributed_JJ from_IN certain_JJ companies_NNS '_POS shareholders_NNS to_TO
other_JJ companies_NNS '_POS shareholders_NNS ._. But_CC the_DT total_JJ amount_NN of_IN value_NN in_IN the_DT industry_NN as_IN
a_DT whole_NN will_MD remain_VB the_DT same_JJ ._.

            In_IN bidding_NN up_RP the_DT prices_NNS of_IN all_PDT these_DT drug_NN companies_NNS ,_, then_RB ,_, investors_NNS are_VBP
essentially_RB saying_VBG that_IN if_IN you_PRP divide_VBP a_DT pie_NN up_RB into_IN four_CD slices_NNS ,_, it_PRP 's_VBZ more_RBR
valuable_JJ than_IN if_IN you_PRP divide_VBP it_PRP up_RP into_IN eight_CD slices_NNS ._. But_CC the_DT pie_NN is_VBZ the_DT very_RB
same_JJ size_NN ._. It_PRP just_RB looks_VBZ different_JJ ._.

            It_PRP 's_VBZ true_JJ that_IN it_PRP 's_VBZ better--all_JJ other_JJ things_NNS being_VBG equal--to_JJ own_JJ one_CD of_IN the_DT
four_CD slices_NNS rather_RB than_IN one_CD of_IN the_DT eight_CD ._. But_CC all_DT other_JJ things_NNS are_VBP n't_RB equal_JJ ,_,
since_IN for_IN Pfizer_NNP to_TO become_VB a_DT $_$ 70_CD billion_CD company_NN ,_, it_PRP 's_VBZ going_VBG to_TO have_VB to_TO spend_VB
huge_JJ amounts_NNS of_IN money_NN to_TO acquire_VB Warner-_NNP Lambert_NNP ._. The_DT possibility_NN of_IN a_DT merger_NN
wave_NN may_MD make_VB the_DT stock_NN of_IN the_DT potential_JJ acquirees_NNS more_RBR valuable_JJ ._. But_CC it_PRP should_MD
make_VB the_DT stock_NN of_IN the_DT potential_JJ acquirers_NNS equally_RB less_RBR valuable_JJ ._.

            The_DT other_JJ possibility_NN is_VBZ that_IN there_EX really_RB will_MD be_VB synergies_NNS in_IN the_DT new_JJ
giant_NN companies_NNS that_WDT will_MD make_VB them_PRP more_RBR profitable_JJ together_RB than_IN they_PRP are_VBP
apart_RB ._. But_CC it_PRP is_VBZ hard_JJ to_TO see_VB what_WP these_DT are_VBP ,_, and_CC empirically_RB ,_, synergies_NNS are_VBP
next_JJ to_TO impossible_JJ to_TO realize_VB ._.

            What_WP that_WDT means_VBZ is_VBZ that_IN the_DT determinants_NNS of_IN value_NN for_IN the_DT industry_NN as_IN a_DT
whole--free_JJ cash_NN flow_NN ,_, return_NN on_IN invested_VBN capital_NN ,_, and_CC future_JJ growth_NN
prospects--will_JJ remain_VB unchanged_JJ after_IN the_DT merger_NN wave_NN is_VBZ done_VBN ._. And_CC that_DT means_VBZ
the_DT stock_NN price_NN of_IN the_DT industry_NN as_IN a_DT whole--if_JJ there_EX were_VBD such_JJ a_DT thing--should_JJ
remain_VB the_DT same_JJ ._.

         
      
   
